Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
Anticancer Res. 2015 Apr ;35(4):2199-204. PMID: 25862878
AIM: The present study aimed to assess the efficacy of 15 mEq magnesium supplied as part of a prehydration regimen in preventing cisplatin-induced nephrotoxicity in patients undergoing therapy with cisplatin-alone (40 mg/m(2)/week) for cervical cancer.
PATIENTS AND METHODS: We studied 28 patients with cervical cancer. This prospective cohort study compared nephrotoxicity in patients who received hydration with and without magnesium sulfate (Mg-hydration group, n=14; non-Mg-hydration group, n=14).
RESULTS: Baseline characteristics, stage of cervical cancer, cisplatin dose and renal function did not differ significantly between the two groups. The serum creatinine level significantly increased from 0.58 to 0.75 mg/dl, and the estimated glomerular filtration rate significantly decreased from 85.1 to 66.5 ml/min by chemotherapy in the non-Mg-hydration group. In contrast, these levels did not change significantly in the Mg-hydration group.
CONCLUSION: A magnesium dose of 15 mEq was found to provide nephroprotective effects among patients with cervical cancer undergoing chemotherapy with cisplatin alone.